Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
12.08. | Novo Nordisk's Alhemo approved by FDA for expanded haemophilia use | ||
12.08. | Biogen/Eisai's Alzheimer's drug Leqembi shows continued benefit over four years | ||
12.08. | Embracing uncertainty in precision medicine communications for lung cancer | ||
11.08. | FDA unveils PreCheck programme to enhance US domestic pharma supply chain | ||
11.08. | Eli Lilly's Mounjaro shown to provide cardiovascular protection in type 2 diabetes patients | ||
11.08. | Patient activation: time to think differently about treatments… | ||
08.08. | MSD receives NICE recommendation for Keytruda in advanced endometrial cancer | ||
08.08. | Novo Nordisk appoints Maziar Mike Doustdar as president and CEO | ||
08.08. | Maximising impact in medical communications: where are we now and where are we heading? | ||
07.08. | Roche's Evrysdi tablets approved by MHRA to treat spinal muscular atrophy | ||
07.08. | Apogee Therapeutics' atopic dermatitis candidate shows promise in phase 2 study | ||
07.08. | Empower or fall behind: why true patient engagement is pharma's competitive edge | ||
06.08. | AstraZeneca's Imfinzi/Imjudo regimen recommended by NICE to treat liver cancer | ||
06.08. | Eli Lilly shares positive results for Jaypirca in head-to-head CLL/SLL study | ||
06.08. | Patient activation - not just a strategy but a necessity | ||
05.08. | BMS and Bain Capital launch new company to develop immunology therapies | ||
05.08. | CHMP recommends BeOne Medicines' Tevimbra for new lung cancer indication | ||
05.08. | Solving the patient engagement value equation | ||
04.08. | Biogen's Qalsody granted MHRA approval to treat rare form of motor neurone disease | ||
04.08. | FDA grants fast track designation to Nektar's rezpegaldesleukin in alopecia areata | ||
04.08. | The power of representation, innovation and trust in rare disease clinical trials | ||
01.08. | Sanofi's Sarclisa approved by EC to treat newly diagnosed multiple myeloma | ||
01.08. | Eli Lilly's Alzheimer's disease drug donanemab recommended by CHMP | ||
01.08. | Patient engagement - a journey of health activation | ||
31.07. | Merck unveils $3bn cost-cutting plan to support pipeline and new product launches |